Evans Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.50 M
as on 12-12-2024
- Company Age 22 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.20 M
as on 12-12-2024
- Revenue -60.09%
(FY 2020)
- Profit 153.80%
(FY 2020)
- Ebitda -68.30%
(FY 2020)
- Net Worth 1.15%
(FY 2020)
- Total Assets 7.98%
(FY 2020)
About Evans Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹1.20 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mini Gopakumar and Gopakumar Vadakemaveettil serve as directors at the Company.
- CIN/LLPIN
U51397KL2002PTC015629
- Company No.
015629
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kozhikode, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Evans Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gopakumar Vadakemaveettil  | Managing Director | 05-Sep-2002 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mini Gopakumar | Director | 03-Sep-2008 | Current |
Financial Performance of Evans Pharmaceuticals.
Evans Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 60.09% decrease. The company also saw a substantial improvement in profitability, with a 153.8% increase in profit. The company's net worth moved up by a moderate rise of 1.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Evans Pharmaceuticals?
In 2016, Evans Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Canara Bank Creation Date: 27 Jul 2004 | ₹0.10 M | Satisfied |
Canara Bank Creation Date: 27 Jan 2004 | ₹1.00 M | Satisfied |
The Canara Bank Creation Date: 27 Jan 2004 | ₹0.10 M | Satisfied |
How Many Employees Work at Evans Pharmaceuticals?
Unlock and access historical data on people associated with Evans Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evans Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evans Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
